Cantor Fitzgerald reiterates Anteris Technologies stock rating at Overweight
Cantor Fitzgerald maintained an Overweight rating and $15.00 price target for Anteris Technologies (AVR). The stock, trading at $6.45, has risen 41% over the past year. The firm reinforced its conviction in AVR's DurAVR device, citing clinical advantages and potential to disrupt the TAVR market. AVR has a market cap of $628.83 million and reported $2.24 million in revenue over the last twelve months.
How this was made
The 30-second read
Why it matters
Analyst endorsement may drive short-term buying, but long-term performance hinges on trial outcomes.
Market read
The rating upgrade could spark modest price appreciation for AVR, with limited spillover to peers.
What to watch
Potential regulatory hurdles and competition from established TAVR players.
Background
Cantor Fitzgerald's reiteration follows a recent fireside chat with Anteris' Chief Medical Officer discussing the DurAVR device.
Ticker impact
Cantor Fitzgerald reiterated an Overweight rating and a $15 price target for Anteris Technologies (AVR).
likely upward pressure as investors price in the higher target.
The new Overweight stance and $15 target represent fresh analyst conviction, which can attract buying interest.
Market effects
May boost confidence in the broader medical device and TAVR market.
Limited to U.S. biotech investors.
Minor, confined to niche cardiovascular device space.
Counterpoint
The rating could be premature if clinical data for DurAVR does not meet expectations.
Key entities
- CompanyAnteris Technologies
Medical device firm developing the DurAVR TAVR platform.
- Research FirmCantor Fitzgerald
Equity research house issuing the Overweight rating.
